Guillain-Barré syndrome presenting with facial diplegia following COVID-19 vaccination in two patients

BMJ Case Rep. 2021 Oct 14;14(10):e244527. doi: 10.1136/bcr-2021-244527.


In March 2020, the WHO declared COVID-19 to be a global pandemic and since December 2020, millions of vaccines have been administered. To date, cases of Guillain-Barré syndrome (GBS) following a COVID vaccine (Pfizer, Johnson & Johnson, Janssen, AstraZeneca) have been reported. A 61-year-old woman developed bilateral asymmetrical lower motor neuron (LMN) facial weakness followed by limb symptoms, 10 days after receiving the first dose of AstraZeneca COVID vaccine. The second patient was a 56-year-old man who, 9 days after receiving first dose of AstraZeneca COVID vaccine, developed bilateral asymmetrical LMN facial weakness with limb symptoms. Intravenous immunoglobulin was administered with rapid recovery. These cases of GBS following the AstraZeneca COVID vaccine add to cohort of patients reported. We flag up to raise awareness of this condition post-COVID-19 vaccine and highlight the prominent bifacial involvement. Early diagnosis and prompt treatment with intravenous immunoglobulin led to rapid recovery.

Keywords: clinical neurophysiology; peripheral nerve disease.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Female
  • Guillain-Barre Syndrome* / chemically induced
  • Guillain-Barre Syndrome* / diagnosis
  • Guillain-Barre Syndrome* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2
  • Vaccination / adverse effects


  • COVID-19 Vaccines